EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through topline data of Phase 3 trials for DURAVYU for wet AMD in 2026 – – Company to host R&D Day in New York on June 26, 2024 – WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments. “We have continued advancing our pipeline through significant milestones including the announcement of topline data from our Phase 2 PAVIA clinical trial of DURAVYU™ in non-proliferative diabetic retinopathy (NPDR),” said Jay Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. “Although th
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $33.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $46.00 to $38.00. They now have an "outperform" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 5/8/24 - Miss
EYPT
Sec Filings
- 5/16/24 - Form 4
- 5/14/24 - Form 144
- 5/9/24 - Form 10-Q
- EYPT's page on the SEC website